PharmaLundensis AB Logo

PharmaLundensis AB

Develops treatments for heavy metal toxicity and serious respiratory illnesses.

PHAL | SPGR

Overview

Corporate Details

ISIN(s):
SE0003359710 (+5 more)
LEI:
54930082I88D5N3GQ506
Country:
Sweden
Address:
Scheelevägen 22, 223 63 Lund
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

PharmaLundensis AB is a pharmaceutical research company that develops treatments for diseases with significant unmet needs. The company's primary project is PHAL-501, a drug designed to bind and excrete heavy metals like mercury, lead, and cadmium from the body. PHAL-501 is intended to act within the intestine, capturing toxins before they are absorbed into the bloodstream, thus offering a potentially safe and effective treatment for heavy metal toxicity. In addition to this focus, the company is also involved in developing therapies for serious respiratory illnesses, such as chronic obstructive pulmonary disease (COPD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PharmaLundensis AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PharmaLundensis AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PharmaLundensis AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Tord Staffan Håkan Skogvall Other Buy 2,337 1,986.45 SEK
2025-01-17 SkåneÖrnen AB Other Buy 121,700 96,143.00 SEK
2025-01-17 Tord Staffan Håkan Skogvall Other Buy 10,958 7,999.34 SEK
2024-10-14 SkåneÖrnen AB Other Buy 49,370 19,748.00 SEK
2024-10-09 Tord Staffan Håkan Skogvall Other Buy 27,936 10,336.32 SEK
2024-09-26 SkåneÖrnen AB Other Buy 63,000 29,610.00 SEK
2024-09-20 Bo Wennergren Other Buy 60,000 27,600.00 SEK

Peer Companies

Company Country Ticker View
ReproCELL Incorporated Logo
Offers stem cell tech, gene editing & drug discovery services for preclinical/clinical research.
Japan 4978
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan 4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan 9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom RGP
ROXX, Inc. Logo
HR tech platform connecting non-desk job seekers with full-time roles using AI and vetting tools.
Japan 241A
SAFTEC CO.,LTD. Logo
Rents and sells safety equipment for construction, from basic supplies to AI/IoT solutions.
Japan 7464
Saniona Logo
Develops ion channel medicines for rare neurological diseases and epilepsy.
Denmark SANION
SBI Leasing Services Co.,Ltd. Logo
Structures Japanese Operating Leases for aircraft & ships for corporate investors.
Japan 5834
Sensorion Logo
Developing gene therapies and small molecules to restore, treat, and prevent hearing loss.
France ALSEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.